Experiencia con toxina botulínica en la migraña crónica

Blumenfeld, 2011, Disability, HRQoL and resource use among chronic and episodic migraineurs: Results from the International Burden of Migraine Study (IBMS), Cephalalgia, 31, 301, 10.1177/0333102410381145 Olesen, 2013, Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edn (beta version), Cephalalgia, 33, 629, 10.1177/0333102413485658 Buse, 2012, Chronic migraine prevalence, disability, and sociodemographic factors: Results from the American Migraine Prevalence and Prevention Study, Headache, 52, 1456, 10.1111/j.1526-4610.2012.02223.x Aurora, 2010, OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial, Cephalalgia, 30, 793, 10.1177/0333102410364676 Diener, 2010, OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial, Cephalalgia, 30, 804, 10.1177/0333102410364677 Dodick, 2010, OnabotulinumtoxinA for treatment of chronic migraine: Pooled results from the double- blind, randomized, placebo-controlled phases of the PREEMPT clinical program, Headache, 50, 921, 10.1111/j.1526-4610.2010.01678.x Aurora, 2014, OnabotulinumtoxinA for chronic migraine: Efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program, Acta Neurol Scand., 129, 61, 10.1111/ane.12171 Aurora, 2011, OnabotulinumtoxinA for treatment of chronic migraine: Pooled analyses of the 56-week PREEMPT clinical program, Headache, 51, 1358, 10.1111/j.1526-4610.2011.01990.x Durham, 2004, Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: Implications for migraine therapy, Headache, 44, 35, 10.1111/j.1526-4610.2004.04007.x Guerzoni, 2016, Increased efficacy of regularly repeated cycles with OnabotululinumtoxinA in MOH patients beyond the first year of treatment, J Headache Pain, 17, 48, 10.1186/s10194-016-0634-9 2013, Global, regional and national incidence, prevalence and years I lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: A systematic analysis for the Global Burden of Disease Study, Lancet, 386, 743 Steiner, 2013, Birbeck GL 2013 Migraine: The seventh disabler, Headache, 53, 227, 10.1111/head.12034 Blumenfeld, 2010, Method of injection of onabotulinumtoxinA for chronic migraine: A safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program, Headache, 50, 1406, 10.1111/j.1526-4610.2010.01766.x Palma, 2012, Clinical experience of treatment with onabotulinumtoxin. A in patients with refractory migraine, Rev Neurol (Barc), 16, 705 Grazzi, 2015, Onabotulinum toxin A (Botox) for chronic migraine treatment: An Italian experience, Neurol Sci, 36, S33, 10.1007/s10072-015-2140-2 Khalil, 2014, Prospective analysis of the use of onabotulinumtoxin A (BOTOX) in the treatment of chronic migraine; real life data in 254 patients from Hukk, UK, J Headache Pain, 15, 54, 10.1186/1129-2377-15-54 Russo, 2016, The use of onabotulinum toxin A (BOTOX) in the treatment of chronic migraine at the Parma Headache Centre: A prospective observational study, Neurol Sci, 37, 1127, 10.1007/s10072-016-2568-z Kollewe, 2016, Long-term treatment of chronic migraine with OnabotulinumtoxinA: Efficacy, quality of life and tolerability in a real-life setting, J Neurol Trans, 123, 533, 10.1007/s00702-016-1539-0 Pagola, 2014, Factores predictores de respuesta al tratamiento con onabotulinumtoxina A en la migraña refractaria, Rev Neurol, 58, 241 Pedraza, 2015, Onabotulinumtoxin A treatment for chronic migraine: Experience in 52 patients treated with the PREEMPT paradigm, SpringerPlus, 4, 176, 10.1186/s40064-015-0957-z Álvaro-González, 2012, Toxina botulínica tipo A en la migraña crónica refractaria: experiencia en uso compasivo preautorización, Rev Neurol, 55, 385 Aurora, 2014, OnabotulinumtoxinA for chronic migraine: Efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program, Acta Neurol Scand., 129, 61, 10.1111/ane.12171 Batty, 2013, The cost-effectiveness of onabotulinumtoxin A for the prophylaxis of headache in adults with chronic migraine in the UK, J Med Econ, 16, 877, 10.3111/13696998.2013.802694 Torres-Ferrús, 2015, Posicionamiento de las unidades de cefalea en el ámbito de la neurología: la importancia de la Onabotulinumtoxin A y otras terapias en el tratamiento de la cefalea, Rev Neurol, 61, S3